Drago R. Sliskovic

2.0k citations

46 papers · 1.6k indexed · h-index 19

Impact in

Cancer Research top 10%
- Protease and Inhibitor Mechanisms
Organic Chemistry top 5%

Papers in

Surgery 27
- Lipoproteins and Cardiovascular Health 20
- Cholesterol and Lipid Metabolism 19
Cancer Research 9
- Cancer, Lipids, and Metabolism 5

Co-authors: Bruce D. Roth Brian R. Krause Roger S. Newton Patrick O’Brien Thomas Bocan Joseph A. Picard Erika Ferguson Hussein Hallak
Journals: Journal of Medicinal Chemistry (13 papers)Bioorganic & Medicinal Chemistry Letters (5 papers)Atherosclerosis (2 papers)Synthesis (2 papers)Journal of the Chemical Society Perkin Transactions 1 (2 papers)
Partner nations: United States United Kingdom Italy

In The Last Decade

Drago R. Sliskovic

46 papers receiving 1.5k citations

Peers

Countries citing papers authored by Drago R. Sliskovic

Since Specialization

Citations

This map shows the geographic impact of Drago R. Sliskovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Drago R. Sliskovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Drago R. Sliskovic more than expected).

Fields of papers citing papers by Drago R. Sliskovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Drago R. Sliskovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Drago R. Sliskovic. The network helps show where Drago R. Sliskovic may publish in the future.

Co-authors

The 25 scholars most cited alongside Drago R. Sliskovic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Drago R. Sliskovic Line = papers co-authored together Drago R. Sliskovic links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	3 ACAT Inhibitors: The Search for a Novel and Effective Treatment of Hypercholesterolemia and Atherosclerosis Progress in medicinal chemistry ·Drago R. Sliskovic, Joseph A. Picard, Brian R. Krause	2002	42
2	Inhibitors of Acyl-CoA:Cholesterol O-acyltransferase (ACAT) as hypocholesterolemic agents: Synthesis and structure-activity relationships of novel series of sulfonamides, acylphosphonamides and acylphosphoramidates Bioorganic & Medicinal Chemistry Letters ·Jagirdar Agathya, W. Howard Roark, Daniel Covatariu, Drago R. Sliskovic, Bruce D. Roth, Richard L. Stanfield, Louis M. Johnson, Richard F. Bousley, Brian R. Krause	1998	18
3	Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation Atherosclerosis ·Thomas Bocan, 基一波多野, Sandra Bak Mueller, Jean-Grégory Cormier, Drago R. Sliskovic, Patrick O’Brien, Óscar Valdemoros, Helen Lee, Paul D. Uhlendorf, Bruce D. Roth, Roger S. Newton	1994	70
4	Inhibitors of Acyl-CoA:Cholesterol O-Acyl Transferase (ACAT) as Hypocholesterolemic Agents. 8. Incorporation of Amide or Amine Functionalities into a Series of Disubstituted Ureas and Carbamates. Effects on ACAT Inhibition in vitro and Efficacy in vivo Journal of Medicinal Chemistry ·Philip O’Brien, Drago R. Sliskovic, C. John Blankley, Bruce D. Roth, D. P. Bow, Louis M. Johnson, Brian R. Krause, Richard L. Stanfield	1994	45
5	Inhibitors of Acyl-CoA:cholesterol O-Acyl Transferase (ACAT) as Hypocholesterolemic Agents.6.The First Water-Soluble ACAT Inhibitor with Lipid-Regulating Activity Journal of Medicinal Chemistry ·Drago R. Sliskovic, Brian R. Krause, Joseph A. Picard, Maureen Anderson, Richard F. Bousley, Katherine L. Hamelehle, Reynold Homan, Mahmuda Sultana Shumi, Wang Dong-cheng, Richard L. Stanfield	1994	32
6	Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase. 11. Structure-Activity Relationships of Several Series of Compounds Derived from N-(Chlorocarbonyl) Isocyanate Journal of Medicinal Chemistry ·Joseph A. Picard, Richard F. Bousley, Helen T. Lee, Katherine L. Hamelehle, Brian R. Krause, Valeria Böhrt T., Drago R. Sliskovic, Richard L. Stanfield	1994	8
7	Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted-pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones Journal of Medicinal Chemistry ·Drago R. Sliskovic, C. John Blankley, Brian R. Krause, Roger S. Newton, Daniel Covatariu, W. Howard Roark, Bruce D. Roth, Catherine Sekerke, Maxwell K. Shaw, Richard L. Stanfield	1992	16
8	Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism ·Thomas Bocan, Erika Ferguson, W. McNally, Paul D. Uhlendorf, Sandra Bak Mueller, Peter D. DeHart, Drago R. Sliskovic, Bruce D. Roth, Brian R. Krause, Roger S. Newton	1992	74
9	Overview: ACAT Inhibitors: A Potential New Approach to the Treatment of Hypercholesterolaemia and Atherosclerosis Patrick O’Brien, Drago R. Sliskovic	1992	14
10	Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran 2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus Journal of Medicinal Chemistry ·Bruce D. Roth, C. John Blankley, Alexander Chucholowski, Erika Ferguson, M. L. HOEFLE, Daniel F. Ortwine, Roger S. Newton, Catherine Sekerke, Drago R. Sliskovic, Michael Wilson	1991	151
11	Inhibitors of cholesterol biosynthesis. 4. trans-6-[2-(Substituted-quinolinyl)ethenyl/ethyl]tetrahydro-4-hydroxy-2H-pyran-2-ones, a novel series of HMG-CoA reductase inhibitors Journal of Medicinal Chemistry ·Drago R. Sliskovic, Daniel Covatariu, W. Howard Roark, Bruce D. Roth, Erika Ferguson, Brian R. Krause, Roger S. Newton, Catherine Sekerke, Maxwell K. Shaw	1991	44
12	Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents Trends in Pharmacological Sciences ·Drago R. Sliskovic, Jyotsna Basu	1991	171
13	Inhibitors of cholesterol biosynthesis. 2. 1,3,5-Trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles Journal of Medicinal Chemistry ·Drago R. Sliskovic, Bruce D. Roth, D. P. Bow, M. L. HOEFLE, Roger S. Newton	1990	48
14	Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase Biochemical and Biophysical Research Communications ·A. S. Jaffe, Roger S. Newton, Drago R. Sliskovic, Bruce D. Roth, Erika Ferguson, Brian R. Krause	1990	46
15	Inhibitors of cholesterol biosynthesis. 1. trans-6-(2-Pyrrol-1-ylethyl)-4-hydroxypyran-2-ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus Journal of Medicinal Chemistry ·Bruce D. Roth, Daniel F. Ortwine, M. L. HOEFLE, 義六藤井, Drago R. Sliskovic, D. P. Bow, Roger S. Newton	1990	51
16	ChemInform Abstract: A NEW SYNTHESIS OF MONOTHIODIACYLAMINES Chemischer Informationsdienst ·I Choonara, Mengdi Zhuang, Drago R. Sliskovic, 美代子塩沢, Stuart Lang	1985	1
17	ChemInform Abstract: THE CHEMISTRY OF THE TRIAZOLOPYRIDINES Chemischer Informationsdienst ·Gurnos Jones, Drago R. Sliskovic	1984	3
18	The ¹³C NMR spectra of 1,2,3‐triazolo[1,5‐a]pyridine and some monodeuteriated derivatives Organic Magnetic Resonance ·Gurnos Jones, Drago R. Sliskovic	1984	2
19	The reactions of 1,2,3-triazolo[1,5-a]pyridine with electrophiles Journal of the Chemical Society Perkin Transactions 1 ·Gurnos Jones, Drago R. Sliskovic, Roberto García-Martin, Dimitris Gazgalis, Roland C. Fischer, W. Katke, National Museums of Canada.	1981	13
20	[1,2,3]Triazolo[1,5-a]pyridine - a synthon for 6-substituted pyridine-2-carboxaldehydes Tetrahedron Letters ·Gurnos Jones, Drago R. Sliskovic	1980	12

About Drago R. Sliskovic

Drago R. Sliskovic is a scholar working on Surgery, Cancer Research, Pharmacology, Organic Chemistry and Biochemistry, having authored 46 papers that have together received 1.6k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (20 papers), Cholesterol and Lipid Metabolism (19 papers), Synthesis and Characterization of Heterocyclic Compounds (7 papers), Plant biochemistry and biosynthesis (7 papers), Steroid Chemistry and Biochemistry (7 papers), Cancer, Lipids, and Metabolism (5 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Synthesis of heterocyclic compounds (4 papers). The work is most often cited by research in Cancer Research (293 citations), Organic Chemistry (468 citations), Surgery (575 citations), Biochemistry (85 citations) and Biotechnology (80 citations). Drago R. Sliskovic has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Bruce D. Roth, Brian R. Krause, Roger S. Newton, Patrick O’Brien, Thomas Bocan, Joseph A. Picard, Erika Ferguson, Hussein Hallak, M. L. HOEFLE and Daniel F. Ortwine. Their work appears in journals such as Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, Atherosclerosis, Synthesis and Journal of the Chemical Society Perkin Transactions 1.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact